Gainers

• OSR Holdings (NASDAQ:OSRH) shares rose 29.2% to $0.59 during Wednesday's after-market session. The company's market cap stands at $19.1 million.
• PROCEPT BioRobotics (NASDAQ:PRCT) stock rose 11.69% to $24.25. The market value of their outstanding shares is at $1.3 billion. As per the press release, Q1 earnings came out today.
• NewcelX (NASDAQ:NCEL) shares moved upwards by 7.89% to $3.69. The market value of their outstanding shares is at $16.9 million.
• Glaukos (NYSE:GKOS) shares rose 7.72% to $126.0. The company's market cap stands at $7.0 billion. The company's, Q1 earnings came out today.
• BiomX (AMEX:PHGE) stock rose 6.84% to $0.68. The company's market cap stands at $7.5 million.
• Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock moved upwards by 6.81% to $4.23. The company's market cap stands at $287.2 million.

Losers

• EUDA Health Holdings (NASDAQ:EUDA) stock fell 8.8% to $13.21 during Wednesday's after-market session. The market value of their outstanding shares is at $30.1 million.
• Shattuck Labs (NASDAQ:STTK) shares declined by 8.33% to $6.5. The market value of their outstanding shares is at $569.1 million.
• Aspire Biopharma Holdings (NASDAQ:ASBP) stock fell 8.28% to $0.22. The market value of their outstanding shares is at $1.0 million.
• Mainz Biomed (NASDAQ:QUCY) stock decreased by 8.08% to $0.42. The market value of their outstanding shares is at $6.2 million.
• Mobile-health Network (NASDAQ:MNDR) stock declined by 7.55% to $0.73. The market value of their outstanding shares is at $4.0 million.
• Scilex Holding (NASDAQ:SCLX) shares declined by 7.41% to $8.0. The market value of their outstanding shares is at $48.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.